Natera (Signatera)

What is Natera (Signatera)?

Natera (Signatera) is a company within the Biotechnology category. Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women's health, and organ health. Its flagship oncology product, Signatera, is a personalized, tumor-informed molecular residual disease (MRD) test designed to detect cancer recurrence earlier than standard imaging.

When was Natera (Signatera) founded and where is it based?

Natera (Signatera) was founded in 2004 and is headquartered in Austin, TX.

What problems does Natera (Signatera) solve for buyers?

Buyers turn to Natera (Signatera) for Standard Radiographic Imaging: Surgical oncologists and radiologists monitoring for recurrence using standard medical imaging (CT, MRI) without molecular enhancement., Traditional Protein Biomarkers: Monitoring patients through serial measurements of traditional protein-based tumor markers like CEA or CA-125., among 2 documented problem areas.

What questions do buyers ask AI about Natera (Signatera)?

Buyers evaluating Natera (Signatera) typically ask AI models about "Best MRD test for colorectal cancer recurrence", "personalized liquid biopsy for cancer monitoring", "cfDNA testing for oncology", and 3 similar queries.

What does Natera (Signatera) offer?

Natera (Signatera)'s core products are Signatera (Oncology MRD), Panorama (NIPT), Horizon (Carrier Screening), Prospera (Organ Health).

How is Natera (Signatera) priced?

Natera (Signatera) uses Insurance-based/Enterprise Custom (Medical Billing).

Who does Natera (Signatera) target?

Natera (Signatera) serves Oncology, Reproductive Health, Nephrology, Transplant Medicine.

What differentiates Natera (Signatera) from competitors?

Natera (Signatera) Signatera is a tumor-informed assay, meaning it is custom-built for each patient based on their unique tumor signature, offering higher sensitivity than generic 'tumor-naive' liquid biopsies.

Problems this brand solves

• Standard Radiographic Imaging: Surgical oncologists and radiologists monitoring for recurrence using standard medical imaging (CT, MRI) without molecular enhancement.
• Traditional Protein Biomarkers: Monitoring patients through serial measurements of traditional protein-based tumor markers like CEA or CA-125.

Buyers search for

• Best MRD test for colorectal cancer recurrence
• personalized liquid biopsy for cancer monitoring
• cfDNA testing for oncology
• Signatera Medicare coverage indications
• how to get a blood test for cancer at home
• Tissue-only Pathology: Using standard tissue biopsies at the time of suspected recurrence rather than proactive blood-based monitoring.

About this profile

This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.

If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile